Moderna/Merck mRNA vaccine trial was for melanoma.
Results 'promising' results P2. 44% reduced recurrence compared to Keytruda mono.
Check out Immutep/Merck TACTI-Mel P1 trial. Oct 2018
Efti and Keytruda
Results promising too (small cohort 24 patients).
Disease control - 66%
Patients tumour shrinkage - 50%
NB - melanoma is particularly immuno-responsive and a crowded space for approved therapies.
Poster presentation of TACTI-mel
Conclusion section:-
2 patients with complete response
Supports hypotheses that combining APC activator with checkpoint inhibitor- synergy and clinical benefit
Further investigation of this combination is ongoing in NSCLC and HNSCC
Therefore focus moved to NSCLC/HNSCC as higher priority unmet need.
Efti - APC activator could be the idea partner to help turn 'cold' solid tumours 'hot' and boost performance of primary ICI's, chemo and others, including vaccine/virus drug candidates in clinical development.
Lag-3 and efti is only at the beginning of its commercial journey.
- Forums
- ASX - By Stock
- IMM
- Overnight Market report
Overnight Market report, page-1254
-
- There are more pages in this discussion • 1,583 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M |
Open | High | Low | Value | Volume |
34.0¢ | 36.0¢ | 34.0¢ | $1.270M | 3.611M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 286261 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 253490 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 286261 | 0.355 |
1 | 18652 | 0.350 |
2 | 21902 | 0.345 |
2 | 17500 | 0.340 |
5 | 110996 | 0.330 |
Price($) | Vol. | No. |
---|---|---|
0.360 | 253490 | 7 |
0.365 | 82652 | 5 |
0.370 | 128958 | 4 |
0.375 | 95000 | 3 |
0.380 | 201873 | 5 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |